- Home
- ALKS
ALKS
Alkermes plc
as 03-28-2025 4:00pm EST
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
| Founded: | 1987 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 4 |
| Market Cap: | 5.4B | IPO Year: | 1991 |
| Target Price: | $39.50 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.17 | EPS Growth: | 3.47 |
| 52 Week Low/High: | $22.90 - $36.45 | Next Earning Date: | 04-30-2025 |
| Revenue: | $1,557,632,000 | Revenue Growth: | -6.36% |
| Revenue Growth (this year): | -8.84% | Revenue Growth (next year): | 4.37% |
Stock Insider Trading Activity of Alkermes plc (ALKS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Parisi Samuel Joseph | ALKS | VP, Finance (Interim PAO) | Feb 26 '25 | Sell | $34.00 | 1,938 | $65,892.00 | 7,717 | |
| Parisi Samuel Joseph | ALKS | VP, Finance (Interim PAO) | Feb 22 '25 | Sell | $35.26 | 3,743 | $131,978.18 | 7,717 | |
| Parisi Samuel Joseph | ALKS | VP, Finance (Interim PAO) | Feb 18 '25 | Sell | $35.69 | 1,327 | $47,360.63 | 7,717 | |
| Hopkinson Craig C. | ALKS | EVP R&D, Chief Medical Officer | Feb 12 '25 | Sell | $34.00 | 349,340 | $11,848,975.19 | 166,708 | |
| Hopkinson Craig C. | ALKS | EVP R&D, Chief Medical Officer | Jan 30 '25 | Sell | $32.05 | 100,918 | $3,234,381.53 | 166,708 |
Latest Alkermes plc News
ALKS Breaking Stock News: Dive into ALKS Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
Deutsche Bank Adjusts Alkermes Public Price Target to $52 From $40, Maintains Buy Rating
PR Newswire
3 days ago
New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder
Zacks
5 days ago
Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition?
Investor's Business Daily
8 days ago
GE Aerospace Leads Five Stocks Near Buy Points With This Bullish Trait
Investor's Business Daily
13 days ago
Cash In On The Luck Of The Irish With 5 St. Patrick's Day Stocks Near Buy Points
Zacks
16 days ago
Why Is Alkermes (ALKS) Down 6.6% Since Last Earnings Report?
Insider Monkey
16 days ago
Is Alkermes plc (ALKS) the Best Healthcare Stock For Long-Term Investment?
Simply Wall St.
16 days ago
Alkermes' (NASDAQ:ALKS) investors will be pleased with their splendid 140% return over the last five years
Compare ALKS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALKS Alkermes plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.